On November 5, 2024, the 7th China International Import Expo (CIIE) commenced in Shanghai, where visitors engaged with various exhibitors, including Organon. Sun Pharmaceutical Industries, India’s largest drugmaker, saw a share price increase of over 7% following the announcement of its all-cash acquisition of Organon & Co., based in New Jersey, for $14 per share.
This strategic move, aimed at enhancing Sun Pharma’s global operations, is designed to boost its sales to $12.4 billion and elevate the company to one of the world’s top 25 pharmaceutical firms. The acquisition aligns with Sun Pharma’s growth strategy for its innovative medicines division, especially in key markets like the U.S., Europe, and China.
Analysts indicate that while such acquisitions can strengthen a company’s portfolio, they may also bring challenges like increased leverage and integration costs in the short term. Organon, which specializes in women’s health and biosimilars, had a significant amount of debt, yet the acquisition is expected to improve the combined company’s financial metrics in the long run. This is not Sun Pharma’s first acquisition aimed at revitalizing its business, having successfully acquired companies like Taro Pharma and Ranbaxy in the past.
Source link
